INTRODUCTION

Postoperative pain management in aesthetic plastic surgery remains a topic of increasing interest amidst heightened awareness of the opioid epidemic. Poorly controlled postoperative pain has been associated with worse surgical outcomes. In patients undergoing thoracic and abdominal surgery, poorly controlled pain has a risk of poor pulmonary function, myocardial ischemia, ileus, thromboembolism, and impaired immune function. Poor pain control in noncosmetic surgeries has been associated with longer postanesthesia care unit (PACU) stays and higher readmission rates; this may cause an undue financial burden on the patient and poor patient satisfaction. Uncontrolled postsurgical pain has been implicated in the development of persistent postsurgical pain due to maladaptive neuronal plasticity and has been implicated in long-term opiate use. This article will review multimodal pain management strategies available to plastic surgeons based on therapeutic classes of medications, and provide a framework for pain management specifically in elective, aesthetic surgery.

OPIOIDS

This class of medications primarily act on mu (μ), kappa (κ), and delta (δ) opioid receptors in the central nervous system. These three opiate receptors are affected differently by various opiates; this may explain the varying effects of this class of medications. Opioids affect afferent pain signals by binding to opiate receptors, thus decreasing the perception of pain. The opiate receptors not only have analgesic properties but also leads to euphoria, sedation, anorexia, and respiratory depression. The addictive potential of opioids has been well established and cannot be overstated with estimates of new persistent opiate use after surgery ranging from 5%–13%. Opioids are administered parenterally or orally. Intravenous administration has predictable peak plasma concentration with rapid time of onset and offset. Intravenous opioids are typically given intraoperatively or in the PACU for aesthetic plastic surgery patients. Oral administration of opioids can offer longer duration of action due to the enteral absorption of the medication, but has slower onset, whereas intravenous administration has a faster and more predictable onset, as intravenous administration avoids first pass metabolism.

Opioids should be used with caution in geriatric patients and patients with morbid obesity, obstructive sleep apnea, and those with abuse history or potential. Plastic surgeons should practice caution in prescribing this class of medication to patients who use other sedative medications such as benzodiazepines, antihistamines, barbiturates, or sleep aids or in patients with excess alcohol consumption.

Disclosure: Dr. Janis receives royalties from Thieme and Springer Publishing. Dr. Joshi has received honoraria from Baxter International Inc and Pacira Bionscience Inc. Dr. Schoenbrunner has no financial interest to declare in relation to the content of this article.
use, as these can have additive effects and cause respiratory depression. 21

We recommend minimizing opiate use postoperatively by employing a multimodal analgesic (MMA) approach to ambulatory and inpatient surgery patients. 22 For patients in whom the surgeon chooses to prescribe opioids for postsurgical pain, we recommend a judicious number of low dose, short-acting opioids that are not combined with acetaminophen. This will allow optimal dosing of acetaminophen without the concerns of overdosing.

**ACETAMINOPHEN**

Acetaminophen’s mechanism of action has yet to be fully elucidated, but it is believed to act in the central nervous system. 23,24 This accounts for its analgesic and antipyretic effects. 25,26 Acetaminophen does not have the same gastric ulceration and bleeding complications associated with nonsteroidal antiinflammatory drugs (NSAIDs). A Cochrane review found that a single postoperative dose of acetaminophen achieves a 50% reduction in pain over 4–6 hours. 27 The maximum dose of acetaminophen is 4000 mg in a 24-hour period in healthy patients who are not taking acetaminophen for extended periods of time (<7 days). 28,29 In healthy patients taking prolonged acetaminophen (>7 days), dosage should be limited to 3000 mg in a 24-hour period. 30 In patients with liver disease, malnutrition, low body weight, geriatric age, or febrile illness, a maximum of 2000 mg in a 24-hour period or total avoidance is recommended. 31

We recommend utilizing acetaminophen in all postoperative patients who do not have contraindications to its use as discussed above. 32,33,34 It should be scheduled around the clock in the first 72 hours after surgery. Plastic surgeons must exercise caution and educate their patients who take at home medications containing acetaminophen such as certain opioid combinations or cold medications.

**NSAIDS AND CYCLO-OXYGENASE (COX)-2 SPECIFIC INHIBITORS**

Traditional NSAIDs, also termed nonselective NSAIDs, act through peripheral inhibition of COX-1 and COX-2 enzymes, inhibiting the synthesis of prostaglandins, mediators of inflammation and vasodilation, and thromboxane, a mediator of vasoconstriction and platelet aggregation. 35 In contrast, COX-2 specific inhibitors do not have any effects on COX-1 enzymes and thus do not influence platelet function. 36

Nonselective NSAIDs can cause gastric ulceration (particularly in postbariatric surgery patients) and gastrointestinal (GI) bleeding. The COX-2 specific inhibitors, a class of NSAIDs, theoretically reduce the risk of GI bleeding but have many of the same contraindications as NSAIDs. Several studies investigating the GI benefits of COX-2 specific inhibitors found they have decreased risk of GI bleeding compared with NSAIDs; however, they are still associated with higher bleeding risk compared with placebo. 37–39 Other potential concerns with this group of drugs include platelet dysfunction, asthma exacerbation, and renal impairment. Plastic surgeons must be aware of the cardiovascular risks associated with NSAIDs. These include myocardial infarction, stroke, heart failure, hypertension, atrial fibrillation, and venous thromboembolism. NSAIDs should be used with caution in patients with cardiovascular disease. 39

Ketorolac tromethamine (Toradol; F. Hoffmann-La Roche AG, Basel, Switzerland) is a nonselective NSAID that is available in intravenous and oral formulation and is widely used due to its rapid onset of action. 40,41 Intravenous ketorolac could be transitioned to any oral NSAID. Plastic surgeons have traditionally been hesitant to use this medication due to concerns for increased bleeding risk. However, a 2015 meta-analysis found that ketorolac does not statistically significantly increase hematoma rates amongst patients undergoing aesthetic surgery (2.5% in patients receiving ketorolac versus 2.4% in patients not receiving ketorolac; P = 0.79). 42 All six studies included in the meta-analysis found a significant reduction in postoperative pain and narcotic use amongst patients who received ketorolac. A recent multisurgeon single-site retrospective cohort study did not find a significant increase in hematoma rates amongst patients undergoing breast reduction (4.0% in patients who received ketorolac versus 3.2% in patients who did not receive ketorolac; P = 0.711) and breast reconstruction (3.2% in patients who received ketorolac versus 1.9% in patients who did not receive ketorolac; P = 0.475). 43

A 2021 systematic review and meta-analysis of 229 articles including 151,031 patients undergoing a wide variety of surgical procedures (including plastic surgery) concluded that NSAIDs are unlikely to be the cause of postoperative bleeding complications, which is consistent across all types of NSAIDs and surgical procedures. 44 A 2021 Cochrane review comparing nonselective NSAIDs (including ketorolac) with placebo, other pain medications, and no medications in breast surgery found little evidence to suggest that NSAIDs affect postoperative bleeding in breast surgery. The authors note that large, high-quality randomized control trials are needed for further clarification on this question. 45

A study investigating the effects of COX-2 specific inhibitors on platelet function found these drugs to have undetectable effects on platelet function similar to placebo, whereas nonselective NSAIDs decreased platelet aggregation and increased bleeding time. 46 Importantly, they carry the same FDA warnings in regard to cardiovascular risks as nonselective NSAIDs. 47,48
In summary, we recommend nonselective NSAIDs or COX-2 specific inhibitors administered intraoperatively and continued postoperatively, unless there are contraindications. At equipotent doses there are no differences in the analgesic effects of nonselective NSAIDs and COX-2 specific inhibitors. We prefer meloxicam because it is administered once a day, which improves patient compliance. Furthermore, meloxicam has greater affinity to COX-2 inhibition compared with COX-1 inhibition, similar to celecoxib. These medications should not be used in patients with active cardiovascular disease, renal impairment, or GI bleeding risk factors. Duration should be minimized to the acute postoperative setting and the lowest effective dosage should be used. Plastic surgeons should consider the use of ketorolac intraoperatively or in the PACU as a powerful adjunct to decrease need for opiates.

ADJUVANT MULTIMODAL MEDICATIONS

Steroids

Steroids have potent and well-known antiinflammatory, immunomodulatory, and antiemetic effects. A single intraoperative dose of dexamethasone has excellent prolonged antiemetic effects, and reduces postoperative pain scores and opioid requirements. Dexamethasone given intravenously has also been shown to prolong regional block, and has an added benefit of providing excellent long-lasting prophylaxis for postoperative nausea and vomiting. In addition, recent studies have shown that IV dexamethasone reduces break through pain reported with single shot blocks. In regard to aesthetic plastic surgery applications, prolonged steroid use causes delayed wound healing, increased surgical site infections, and hyperglycemia. However, several meta-analyses have found that a single dose of dexamethasone does not influence wound healing complications or surgical site infections. In our practice, cyclobenzaprine is most commonly prescribed. Despite its classification, cyclobenzaprine does not act on skeletal muscle. Rather, it is a centrally-acting medication believed to act at the brain stem level on the locus ceruleus, decreasing the activity of serotonergic descending neurons, thereby decreasing muscle tone. The effect on the locus ceruleus may help explain the sedating qualities of the medication. Cyclobenzaprine, and most other muscle relaxants, are renally metabolized and require dose adjustments for patients with renal impairment.

Muscle Relaxants

Muscle relaxants represent a broad category of medications. In our practice, cyclobenzaprine is most commonly prescribed. Despite its classification, cyclobenzaprine does not act on skeletal muscle. Rather, it is a centrally-acting medication believed to act at the brain stem level on the locus ceruleus, decreasing the activity of serotonergic descending neurons, thereby decreasing muscle tone. The effect on the locus ceruleus may help explain the sedating qualities of the medication. Cyclobenzaprine, and most other muscle relaxants, are renally metabolized and require dose adjustments for patients with renal impairment.

Within plastic surgery, muscle relaxant use has poor evidence for improvement in pain control and postoperative opioid use. A recent retrospective review study of scheduled cyclobenzaprine use after implant-based subpectoral breast reconstruction found muscle relaxant use did not significantly decrease pain scores nor opiate consumption.

Due to the lack of evidence of muscle relaxant use within an MMA protocol and given the risks of sedation in combination with opiates, we do not recommend the routine use of muscle relaxants as adjuncts in an MMA regimen. We recommend special caution in elderly patients as this class of medication can worsen fall risk and delirium.

Topical Local Anesthetics

Topical local anesthetics inactivate voltage-gated sodium channels, raising the threshold required to generate an action potential, rendering the area temporarily insensitive. These medications preferentially affect type C nerve fibers (pain fibers) over type A nerve fibers (proprioception and pressure fibers); patients may therefore continue to feel pressure sensation without feeling pain during the procedure.
Table 1. Local Anesthetic Dosing Recommendations

| Anesthetic   | Onset    | Duration of Analgesia | Maximum Dose without Epinephrine | Maximum Dose with Epinephrine |
|--------------|----------|-----------------------|----------------------------------|------------------------------|
| Lidoceaine   | 10–20 min| 3–8 h                 | 4.5 mg/kg                        | 7 mg/kg                      |
| Mepivacaine  | 10–20 min| 3–10 h                | 5 mg/kg                          | 7.5 mg/kg                    |
| Ropivacaine  | 15–30 min| 5–24 h                | 3 mg/kg                          | 3.5 mg/kg                    |
| Bupivacaine  | 15–30 min| 5–30 h                | 2.5 mg/kg                        | 3 mg/kg                      |

The most commonly used topical anesthetics include lidocaine patches, eutectic mixture of local anesthetics consisting of lidocaine and prilocaine, as well as a mixture of lidocaine, epinephrine, and tetracaine. The concentrations of each local anesthetic vary and must be carefully calculated to avoid local anesthetic systemic toxicity. Guidelines are available from the American Society of Regional Anesthesia and Pain Medicine. Topical anesthetics may be of special benefit in aesthetic patients undergoing filler injection for preprocedure numbing.

Local Infiltration Anesthesia/Analgesia

Local infiltration anesthesia/analgesia commonly includes lidocaine, bupivacaine, and ropivacaine administered at the surgical site. These anesthetics are often combined with epinephrine to decrease intraoperative blood loss. Lalonde has revolutionized wide awake, in-office surgery with injection techniques that minimize discomfort and maximize efficacy. Local infiltration analgesia not only allow for painless awake office procedures, but also minimize postoperative pain. A meta-analysis found that local anesthetic injected before incision decreases pain and decreases postoperative analgesic consumption and time to first rescue pain medication dose.

Liposomal bupivacaine (Exparel; Pacira Biosciences Inc; Parsippany, N.J.) contains bupivacaine within a lipid-based vehicle that results in diffusion of the drug over time to first rescue pain medication dose. Liposomal bupivacaine has been shown to provide pain relief over 48–72 hours. Liposomal bupivacaine remains under patent and thus costs more than standard bupivacaine. A study by Little et al found decreased postoperative narcotic consumption, length of stay, direct and total costs, and 30-day readmission rate with liposomal bupivacaine compared with control patients undergoing abdominal wall, implant-based, and autologous breast reconstruction.

We recommend the use of short-acting local anesthetics for bedside procedures and long-acting local anesthetics for postprocedure pain control. In aesthetic plastic surgery patients undergoing ambulatory surgery, liposomal bupivacaine may provide significant pain relief in the acute postoperative period warranting the increased cost.

Tumescent Analgesia

Tumescent analgesia involves the use of dilute lidocaine or bupivacaine in large volumes of carrier fluid with or without epinephrine. This technique was popularized by Klein in the late 1980s for use during liposuction and its use has since been widely expanded. Due to the lipid solubility and distributive properties of local anesthetics, tumescent analgesia allows for higher maximum concentrations of local anesthetics than traditional field blocks. Studies measuring the maximum safe dosage of lidocaine in wetting solution have been found to be 35 mg per kg, with more recent reports showing safety profiles up to 55 mg per kg. The American Society of Plastic Surgeons Practice Advisory on Liposuction recommends limiting lidocaine to a maximum dose of 35 mg per kg (only when used as part of wetting solution).

Tumescent analgesia is frequently used in abdominoplasty procedures with reports of the technique being used with deep sedation and conscious sedation for in-office procedures. Tumescent techniques are frequently combined with liposuction during abdominoplasty, a technique known as liposabdominoplasty. This procedure carries with it an inherent risk of vascular compromise due to the theoretical risk of disrupting blood supply to the abdominal skin flaps. This complication can be minimized by performing only selective undermining of the skin flaps to the portion of the abdomen requiring rectus muscle plication, thereby preserving the lateral row of rectus muscle perforators.

A 2019 systematic review of 17 liposabdominoplasty studies encompassing 14,061 patients found fewer complications in the liposabdominoplasty group compared with the traditional abdominoplasty group (RR 0.85; CI 0.71–0.97; P = 0.017) with the liposabdominoplasty group having a lower incidence of hematoma (RR = 0.56; 95% CI 0.36–0.86; P = 0.009) and seroma (RR = 0.69; 95% CI 0.57–0.85; P = 0.000) compared with the traditional abdominoplasty group.

Tumescent analgesia can also be used for breast surgery. Breast reductions have been carried out under intravenous sedation and tumescent analgesia with reports of 516–2948 g resection specimens, thus avoiding the need for general anesthesia. A 2012 meta-analysis of 13 articles of tumescent analgesia used during breast reduction found that patients who underwent tumescent analgesia had an average of 202 cm³ less blood loss compared with patients without tumescent analgesia (P < 0.001). There was also a significant reduction in the need for postoperative blood transfusion amongst patients who received tumescent analgesia (OR 0.05). Tumescent analgesia has also been reported for use in breast augmentation under intravenous sedation, including submuscular implant placement, with a higher than average mixture of tumescent analgesia (100 cm³ of 1% lidocaine with 1:100,000 epinephrine mixed with 250 cm³ of normal saline). Tumescent analgesia has also been reported as an adjunct...
to implant capsulectomy in technique papers to facilitate dissection through hydrodissection and to minimize intraoperative blood loss. 105,106 Tumescent analgesia is routinely used for rhytidectomy to facilitate dissection and minimize intraoperative blood loss. Tumescent analgesia can also allow for rhytidectomy to be performed under oral or intravenous sedation in the office. 93 The precise composition of the wetting solution varies widely between surgeons based on the total amount of wetting solution injected; standard guidelines for local anesthetic dosages should be respected. We recommend the routine use of wetting solution in a superwet manner with lidocaine or bupivacaine, as described by Fodor, within the safety profile of each respective local anesthetic for liposuction. 107,108

Regional Anesthesia

Regional anesthesia involves injecting long-acting local anesthetic into a targeted area surrounding peripheral nerves (either perineurally or in the fascial planes).109 Regional anesthesia is a key component of MMA technique as it has been shown to decrease postoperative pain scores and postoperative opioid use, as well as opioid-related adverse events.110–114 The most commonly used regional anesthetic techniques within aesthetic plastic surgery include the interfascial plane blocks such as pectoralis (PECS) I and II block and the erector spinae plane blocks in breast surgery, as well as the transversus abdominis plane block and rectus abdominis muscle block for abdominal surgery.109

The PECS I block is performed by injecting 20 cm3 of long-acting local anesthetic into the fascial plane between the pectoralis major and minor muscle to blunt burning sensation from the pectoral and intercostobrachial nerves.115–118 The PECS II block is performed by injecting 10–20 cm3 of local anesthetic between the pectoralis minor and serratus anterior muscle at the level of the third rib to blunt intercostal nerves 3–6 and the long thoracic nerves.119

Table 2. Multimodal Analgesia Options

| Medication / Technique | Timing                   | Dosage                                   | Duration           | Contraindications / Caution                        |
|------------------------|--------------------------|------------------------------------------|--------------------|---------------------------------------------------|
| Local and/or regional analgesia | Preoperatively or intraoperatively | Local anesthetic maximum dosage | Depends on local anesthetic used | Local anesthetic systemic toxicity                  |
| Acetaminophen          | Preoperative dose or intraoperatively continued postoperatively | 1000 mg preoperative // 1000 mg q6 hours postoperative | Continue until healing | Liver disease                                      |
| NSAID                  | Intraoperatively continued postoperatively | Ketorolac 15–30 mg IV // Meloxicam 15 mg 600 mg preoperative dose // 100–300 mg TID | Continue 5 days after surgery | Cardiac or renal disease; caution in patients at risk for GI bleeding |
| Gabapentin             | Preoperative and continued postoperatively | | Discontinue as soon as able | Avoid in elderly, morbidly obese, obstructive sleep apnea, and patients requiring high opioid doses after surgery; caution in patients with renal impairment |
| Cyclobenzaprine        | Postoperatively           | 5–10 mg TID PRN                          | Discontinue as soon as able | Caution in geriatric patients and those requiring higher doses of opiates |
| Oxycodone              | Postoperatively           | 5 mg q3-4h PRN                           | Discontinue as soon as able | Use only as rescue (breakthrough pain)               |

PRN: as needed; TID: three times daily.

Table 3. Alternative MMA Options

| Medication / Technique | Alternatives | Dosage                                   | Duration           | Contraindications / Caution                        |
|------------------------|--------------|------------------------------------------|--------------------|---------------------------------------------------|
| Acetaminophen          | None         | 1000 mg q6h                              | Up to 7 days after surgery | Severe liver disease                                |
| Celecoxib              | Ibuprofen    | 600–800 mg q8h                           | Up to 7 days after surgery | Cardiac or renal disease; caution in patients at risk for GI bleeding |
| Ketorolac (IV)         | Meloxicam (PO) | 15–30 mg, intraoperatively 300–600 mg, q8h Pregabalin: 75 mg q12h | Intraoperative Up to 5–7 days after surgery | Same as celecoxib Can cause somnolence; respiratory depression when combined with high dose opioids; requires dose adjustment in renal impairment |
| Gabapentin             | Pregabalin   | 300–600 mg q8h                           | Up to 5–7 days after surgery | Requires dose adjustment in renal impairment |
| Cyclobenzaprine        | Tizanidine   | 2 mg q8h; increase by 2–4 mg to max dose 36 mg in 24 hours Methocarbamol (PO) 1000 mg q 6h | Up to 5–7 days after surgery | Requires dose adjustment in renal impairment |
| Hydrocodone            | 5 mg q3-4h, PRN for breakthrough pain if initiated inpatient | Continue 5 days after discharge Discontinue as soon as able | Requires dose adjustment in renal impairment | Contains acetaminophen—decrease other sources of acetaminophen |
| Oxycodone              | Morphine (PO) | 15–30 mg q3-4h PRN | Discontinue as soon as able | |
| IV hydromorphone       | Morphine (IV) | 2.5–5 mg q3-4h, PRN Morphine (IV) 50–100 mcg q1-2h PRN | Discontinue as soon as able | |

CLD: clear liquid diet; PRN: as needed; TID: three times daily.
nerves. \(^{115-118}\) The PECS blocks are traditionally performed under ultrasound guidance but can also be performed under direct visualization intraoperatively. The erector spinae plane block is performed under ultrasound guidance by injecting \(20 \text{ cm}^3\) of local anesthetic between the rhomboid major and erector spinae muscle; this provides anesthesia from the T2 to T9 level from the midclavicular line to 3 cm lateral of midline from the thoracic spine. \(^{119}\)

The transversus abdominis plane block is performed by injecting local anesthetic between the internal oblique and transversus abdominis fascial planes, blunting the afferent sensory pain fibers of the terminal branches of T10-L1. \(^{121}\) The rectus abdominis muscle block is more limited to the rectus abdominis muscle in the distribution of T7-L1. \(^{121}\) The rectus abdominis muscle block is best used for vertical midline incisions. \(^{122,123}\)

We recommend the use of regional anesthesia whenever possible. Because regional anesthesia utilizes local anesthetics, the same caution in regard to local anesthetic toxicity must be employed.

**Putting It All Together: MMA Regimen**

In a time when the United States struggles to confront a growing opiate epidemic, surgeons must be ever mindful of their postoperative analgesic approach. We have adapted the lessons learned from our own institutional experience to develop an MMA regimen to treat postsurgical pain in aesthetic plastic surgery patients. \(^{124-126}\) Table 2 summarizes our recommendations for MMA options that can be customized based on the unique surgical procedure and patient characteristics. Table 3 provides alternative medication options for an MMA regimen. Patients with allergies to the medications listed in Table 2 should either not be given these medications or be given alternative medications within the same drug class depending on the severity of their allergy. Treatment with these multimodal regimens should be limited to the shortest duration of time possible to minimize risk of complications from medication overuse.

**References**

1. Joshi GP, Ogunnaíke BO. Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain. *Anesth Analg*. 2005;91:21-36.

2. Baratta JL, Schwenk ES, Viscusi ER. Clinical consequences of inadequate pain relief: barriers to optimal pain management. *Plast Reconstr Surg*. 2014;134(4 Suppl 2):15S-21S.

3. Pavlin DJ, Chen C, Penaloza DA, et al. A survey of pain and other symptoms that affect the recovery process after discharge from an ambulatory surgery unit. *J Clin Anesth*. 2004;16:206-206.

4. Herbst MO, Price MD, Soto RG. Pain related readmissions/ revisitss following same-day surgery: have they decreased over a decade? *J Clin Anesth*. 2017;42:15.

5. Coley KC, Williams BA, DaPos SV, et al. Retrospective evaluation of unanticipated admissions and readmissions after same day surgery and associated costs. *J Clin Anesth*. 2002;14:349-353.

6. Pavlin DJ, Chen C, Penaloza DA, et al. Pain as a factor complicating recovery and discharge after ambulatory surgery. *Anesth Analg*. 2002;95:627-634, table of contents.

7. Pavlin DJ, Rapp SE, Polissar NL, et al. Factors affecting discharge time in adult outpatients. *Anesth Analg*. 1998;87:816-826.

8. Wu CL, Naqibuddin M, Rowlingson AJ, et al. The effect of pain on health-related quality of life in the immediate postoperative period. *Anesth Analg*. 2005;97:1078-1085.

9. Joshi GP, Kehlet H. Postoperative pain management in the era of ERAS: an overview. *Best Pract Res Clin Anaesthesiol*. 2013;27:259-267.

10. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. *Lancet*. 2006;367:1618-1625.

11. Belocil H, Sulpice L. Peri-operative pain and its consequences. *J Vasc Surg*. 2016;153(6S):S15-S18.

12. Pasternak GW. Opiate pharmacology and relief of pain. *J Clin Oncol*. 2014;32:1655-1661.

13. Segredo V, Burford NT, Lameh J, et al. A constitutively internalizing and recycling mutant of the mu-opioid receptor. *J Neurochem*. 1997;68:2395-2404.

14. Chu P, Murray S, Lissin D, et al. Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. *J Biol Chem*. 1997;272:27124-27130.

15. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. *Pain Physician*. 2008;11(suppl 2):S13-S153.

16. Brummett CM, Waljee JF, Goel G, et al. New persistent opioid use after minor and major surgical procedures in US Adults. *JAMA Surg*. 2017;152:e170504.

17. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. *J Hand Surg Am*. 2016;41:947-957.e3.

18. Jiang X, Orton M, Feng R, et al. Chronic opioid usage in surgical patients in a large academic center. *Ann Surg*. 2017;265:722-727.

19. Alexander JC, Patel B, Joshi GP. Perioperative use of opioids: current controversies and concerns. *Best Pract Res Clin Anaesthesiol*. 2019;33:341-351.

20. Shanithana H, Ladha KS, Kehlet H, et al. Perioperative opioid administration. *Anesthesiology*. 2021;134:645-659.

21. Funk RD, Hilliard P, Ramachandran SK. Perioperative opioid usage: avoiding adverse effects. *Plast Reconstr Surg*. 2014;134(4 Suppl 2):32S-39S.

22. Janis JE, Joshi G. Introduction to the pain management supplement in plastic surgery. *Plast Reconstr Surg*. 2014;134:66s-7s.

23. Ghanem CI, Pérez MJ, Manautou JE, et al. Acetaminophen from the 1940s to 2021: Are we still in the dark? *JAMA*. 2021;325:602-610.
Schoenbrunner et al. • Multimodal Analgesia in Plastic Surgery

27. Tomás L, McQuay HJ, Derry S, et al. Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database Syst Rev. 2008;2008:CD006622.

28. Krenzelok EP, Royal MA. Confusion: Acetaminophen dosing changes based on NO evidence in adults. Drugs R D. 2012;12:45–48.

29. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity—where do we go from here? Expert Opin Drug Saf. 2007;6:341–355.

30. Liu FC, Yu HP, Liao CC, et al. The timing and effects of low-dose ethanol treatment on acetaminophen-induced liver injury. Life (Basel). 2021;11:1094.

31. Hayward KL, Powell EE, Irvine KM, et al. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016;81:210–222.

32. Barker JC, Joshi GP, Janis JE. Basics and best practices of multimodal pain management for the plastic surgeon. Plast Reconstr Surg Glob Open. 2020;8:e2833.

33. Schoenbrunner AR, Janis JE. Pain management in plastic surgery. Clin Plast Surg. 2020;47:191–201.

34. Caudhman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52(suppl 5):13–23.

35. Bosch DJ, Nieuwenhuijs-Mokee GJ, van Meurs M, et al. Immune modulatory effects of nonsteroidal anti-inflammatory drugs in the perioperative period and their consequence on postoperative outcome. Anaesthesiology. 2022;126:843–860.

36. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921–1928.

37. Emery P, Zeidler H, Krien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354:2106–2111.

38. Bombardier C, Laine L, Reicin A, et al.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–8, 2 p following 1528.

39. Pepine CJ, Gurbel PA. Cardiovascular safety of NSAIDs: additional insights after PRECISION and point of view. Clin Cardiol. 2017;40:1352–1356.

40. Vadivelu N, Gowda AM, Urman RD, et al. Ketorolac tromethamine—routes and clinical implications. Pain Pract. 2015;15:175–193.

41. Plapler PG, Scheinberg MA, Ecclissato Cda C, et al. Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Des Devel Ther. 2016;10:1987–1993.

42. Stephens DM, Richards BG, Schleicher WF, et al. Is ketorolac safe to use in plastic surgery? A critical review. Aesthet Surg J. 2015;35:462–466.

43. Nguyen BN, Barta RJ, Stewart CE, et al. Toradol following breast surgery: is there an increased risk of hematoma? Plast Reconstr Surg. 2018;141:814–817e.

44. Bongiovanni T, Lancaster E, Ledesma Y, et al. Systematic review and meta-analysis of the association between non-steroidal anti-inflammatory drugs and operative bleeding in the perioperative period. J Am Coll Surg. 2021;229:765–780.e1.

45. Klifto KM, Elhelali A, Payne RM, et al. Perioperative systemic non-steroidal anti-inflammatory drugs (NSAIDs) in women undergoing breast surgery. Cochrane Database Syst Rev. 2021;11:CD013290.

46. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124–132.

47. Bresalier RS, Sandler RS, Quan H, et al.; Adenomatous Polypl Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.

48. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ. 2004;171:1027–1028.

49. Waldron NH, Jones CA, Gan TJ, et al. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. Br J Anaesth. 2013;110:191–200.

50. De Oliveira GS Jr, Almeida MD, Benzon HT, et al. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011;115:575–588.

51. Bigat Z, Boztug N, Hadimioglu N, et al. Does dexamethasone improve the quality of intravenous regional anesthesia and analgesia? A randomized, controlled clinical study. Anesth Analg. 2006;102:605–609.

52. Chung MA, Berbenetz NM, Lin C, et al. Perineural versus intravenous dexamethasone as an adjuvant for peripheral nerve blocks: a systematic review and meta-analysis. Reg Anesth Pain Med. 2017;42:319–326.

53. Barry GS, Bailey JC, Sardinha J, et al. Factors associated with rebound pain after peripheral nerve block for ambulatory surgery. Br J Anaesth. 2021;116:862–871.

54. Myles PS, Corcoran T. Benefits and risks of dexamethasone in noncardiac surgery. Anaesthesiology. 2021;135:895–903.

55. Bjorn S, Linde F, Nielsen KK, et al. Effect of perineural dexamethasone on the duration of single injection saphenous nerve block for analgesia after major ankle surgery: a randomized, controlled trial. Reg Anesth Pain Med. 2017;42:210–216.

56. Low YH, Gan TJ. NMDA receptor antagonists, gabapentinoids, et-2 agonists, and dexamethasone and other non-opioid adjuvants: do they have a role in plastic surgery? Plast Reconstr Surg. 2014;134(4 Suppl 2):695–828.

57. Thorén H, Snåll J, Kormi E, et al. Does perioperative glucocorticosteroid treatment correlate with disturbance in surgical wound healing after treatment of facial fractures? A retrospective study. J Oral Maxillofac Surg. 2009;67:1884–1888.

58. Snåll J, Kormi E, Lindqvist C, et al. Impairment of wound healing after operative treatment of mandibular fractures, and the influence of dexamethasone. Br J Oral Maxill. Surg. 2013;51:808–812.

59. Ali Khan S, McDonagh DL, Gan TJ. Wound complications with dexamethasone for postoperative nausea and vomiting prophylaxis: a moot point? Anesth Analg. 2013;116:966–968.

60. Polderman JA, Farhang-Razi V, Van Dieren S, et al. Adverse side effects of dexamethasone in surgical patients. Cochrane Database Syst Rev. 2018;11:CD011940.

61. Asehounou K, Le Moal C, Lebuffe G, et al.; PACMAN study group. Effect of dexamethasone on complications or all cause mortality after major non-cardiac surgery: multicentre, double blind, randomised controlled trial. BMJ. 2021;373:n1162.

62. Corcoran TB, Myles PS, Forbes AB, et al.; PADDI Investigators; Australian and New Zealand College of Anaesthetists Clinical Trials Network; Australasian Society for Infectious Diseases Australian and New Zealand College of Anaesthetists Clinical Trials Network. Dexamethasone and surgical-site infection. N Engl J Med. 2021;384:1731–1741.

63. Neff SP, Stapelberg F, Warmington A. Excruciating perineal pain after operative treatment of mandibular fractures, and the influence of dexamethasone. Br J Oral Maxill. Surg. 2013;51:808–812.

64. Chang CY, Challa CK, Shah J, et al. Gabapentin in acute postoperative pain. Br J Anaesth. 2021;115:575–588.

65. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(6 Suppl 5):S17–S22; discussion S31.

66. Beydoun A, Uthman BM, Sackellares JC. Gabapentin: Pharmacokinetics, efficacy, and safety. Clin Neuropharmacol. 1995;18:469–481.
67. Verret M, Lauzier F, Zarychanski R, et al.; Canadian Perioperative Anesthesia Clinical Trials (PACT) Group. Perioperative use of gabapentinoids for the management of postoperative acute pain: a systematic review and meta-analysis. *Anesthesiology*. 2020;133:265–279.

68. Tinsbloom B, Muckler VC, Stoeckel WT, et al. Evaluating the implementation of a preemptive, multimodal analgesia protocol in a plastic surgery office. *Plast Surg Nurs.* 2017;37:137–143.

69. Bykow K, Bateman BT, Franklin JM, et al. Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States. *JAMA Netw Open*. 2020;3:e203167.

70. Sarac BA, Schoenbrunner AR, Brower KL, et al. Analysis of adverse effects of multimodal gabapentin in abdominal wall reconstruction. *Plast Reconstr Surg*. 2022;149:733–739.

71. Mao J, Chen LL. Gabapentin in pain management. *Anesth Analg*. 2000;91:680–687.

72. Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. *Eur J Pharmacol*. 1996;311:29–35.

73. Honda M, Nishida T, Ono H. Tricyclic analog cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. *Eur J Pharmacol*. 2003;458:91–99.

74. Al Yafi MN, ElHawary H, Al-Halabi B, et al. Pain control following hand surgery. *J Hand Surg Am*. 2013;38:443–447.

75. Kumar M, Chawda R, Goyal M. Topical anesthesia. *J Anaesthesiol Clin Pharmacol*. 2015;31:450–456.

76. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. *Anesth Prog*. 2012;59:90–101; quiz 102–103.

77. El-Boghdady K, Pawa A, Chin KJ. Local anesthetic systemic toxicity: 2017 version. *Reg Anesth Pain Clin*. 2018;43:150–153.

78. Butterworth J IV. Clinical Pharmacology of Local Anesthetics. Available at https://www.nysora.com/foundations-of-regional-anesthesia/pharmacology-clinical-pharmacology-local-anesthetics/. Accessed November 24, 2021.

79. Neal JM, Woodward CM, Harrison TK. The American Society of Regional Anesthesia and Pain Medicine checklist for managing local anesthetic systemic toxicity: 2017 version. *Reg Anesth Pain Med*. 2018;43:150–153.

80. Farhangkhoei H, Lalonde J, Lalonde DH. Teaching medical students and residents how to inject local anesthesia almost painlessly. *Can J Plast Surg*. 2012;20:169–172.

81. Lalonde D, Martin A. Epinephrine in local anesthesia in finger and hand surgery: the case for wide-awake anesthesia. *J Am Acad Orthop Surg*. 2013;21:443–447.

82. Lalonde DH, Wong A. Dosage of local anesthesia in wide awake hand surgery. *J Hand Surg Am*. 2013;38:2025–2028.

83. Lovely LM, Chishiti YZ, Woodland JL, et al. How much volume of local anesthesia and how long should you wait after injection for an effective wrist median nerve block? *Hand (N Y)*. 2018;13:281–284.

84. Strazar AR, Leynes PG, Lalonde DH. Minimizing the pain of local anesthesia injection. *Plast Reconstr Surg*. 2013;132:673–684.

85. Lalonde D, Wong A. Local anesthetics: What’s new in minimal local injection and best evidence in pain control. *Plast Reconstr Surg*. 2014;134(4 Suppl 2):405–409.

86. Lalonde DH. Latest advances in wide awake hand surgery. *Hand Clin*. 2019;35:1–6.

87. Joshi GP, Machi A. Surgical site infiltration: a neuroanatomical approach. *Best Pract Res Clin Anaesthesiol*. 2019;33:317–324.

88. Ong CK, Lirk P, Seymour RA, et al. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. *Anesth Analg*. 2005;100:757–773.

89. Dosing and Administration. Available at: https://www.exparel.com/hcp/about-exparel/dosing-and-administration. Accessed November 24, 2021.

90. Chahar P, Cummings KC III. Liposomal bupivacaine: a review of a new bupivacaine formulation. *J Pain Res*. 2012;5:257–264.

91. Little A, Brower K, Keller D, et al. A cost-minimization analysis evaluating the use of liposomal bupivacaine in reconstructive plastic surgery procedures. *Plast Reconstr Surg*. 2019;143:1269–1274.

92. Klein JA. Tumescent technique chronicles. local anesthesia, liposuction, and beyond. *Dermatol Surg*. 1995;21:449–457.

93. Gutowski KA. Tumescent analgesia in plastic surgery. *Plast Reconstr Surg*. 2014;134(4 Suppl 2):508–578.

94. Klein JA. Tumescent technique for regional anesthesia permits lidocaine doses of 55 mg/kg for liposuction. *J Dermatol Surg Oncol*. 1990;16:248–263.

95. Ostad A, Kageryama N, Moy RL. Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction. *Dermatol Surg*. 1996;22:921–927.

96. ASPS Committee on Patient Safety. *Practice Advisory on Liposuction: Executive Summary*. Arlington Heights, Ill.: American Society of Plastic Surgeons; 2008.

97. Kryger ZB, Fine NA, Mustoe TA. The outcome of abdominoplasty performed under conscious sedation: Six-year experience in 153 consecutive cases. *Plast Reconstr Surg*. 2004;113:1807–1817; discussion 1818.

98. Friedland JA, Maffi TR. MOCS-SM (CME article: Abdominoplasty. *Plast Reconstr Surg*. 2008;121(4 Suppl):1–11.

99. Nahai F. *The Art of Aesthetic Surgery: Principles & Techniques*. New York, N.Y.: Thieme Publishers; 2005.

100. Landair A, Rubin J. *Applied Anatomy in Body Contouring*. New York, N.Y.: Thieme Publishers; 2005.

101. Xia Y, Zhao J, Cao DS. Safety of lipoabdominoplasty versus abdominoplasty: a systematic review and meta-analysis. *Aesthetic Plast Surg*. 2019;43:167–174.

102. Zukowski ML, Ash K, Klink B, et al. Breast reduction under intravenous sedation: a review of 50 cases. *Plast Reconstr Surg*. 1996;97:952–956; discussion 957.

103. Hardwicke JT, Jordan RW, Skillman JM. Infiltration of epinephrine in reduction mammoplasty: a systematic review of the literature. *Plast Reconstr Surg*. 2012;130:773–779.

104. Gart MS, Ko JH, Heyer KS, et al. Breast implant procedures under conscious sedation: a 6-year experience in 461 consecutive patients. *Plast Reconstr Surg*. 2013;131:1169–1178.

105. Solomon MP. Tumescent technique as an adjunct to breast implant removal and capsulotomy. *Ann Plast Surg*. 2000;44:495–497.

106. Silfen R, Vilain A, Wohl I, et al. Tumescent technique in capsulotomies: a useful adjunct. *Plast Reconstr Surg*. 2004;114:602.

107. Rohrjch RJ, Kenkel JM, Janis JE, et al. An update on the role of subcutaneous infiltration in suction-assisted lipectomy. *Plast Reconstr Surg*. 2003;111:926–937; discussion 928.

108. Horton JB, Reece EM, Broughton G II, et al. Patient safety in the office-based setting. *Plast Reconstr Surg*. 2006;117:61e–80e.

109. Machi A, Joshi GP. Interfacial plane blocks. *Best Pract Res Clin Anaesthesiol*. 2019;33:303–315.

110. Schnabel A, Reichl SU, Kranke P, et al. Efficacy and safety of paraverbral blocks in breast surgery: a meta-analysis of randomized controlled trials. *BJA Anaesth*. 2010;105:842–852.

111. Tahiri Y, Tran DQ, Bouteaud J, et al. General anaesthesia versus local anaesthesia for outpatient reduction mammoplasty: a systematic review and meta-analysis. *PRS Global Open*. 2022.
Fayezizadeh M, Majumder A, Neupane R, et al. Efficacy of transversus abdominis plane block with liposomal bupivacaine during open abdominal wall reconstruction. *Am J Surg.* 2016;212:399–405.

Rundgren J, Mellstrand Navarro C, Ponzer S, et al. Regional or general anesthesia in the surgical treatment of distal radial fractures: a randomized clinical trial. *J Bone Joint Surg Am.* 2019;101:1168–1176.

Blanco R. The ‘pecs block’: a novel technique for providing analgesia after breast surgery. *Anaesthesia.* 2011;66:847–848.

Blanco R, Fajardo M, Parras Maldonado T. Ultrasound description of pecs II (modified pecs I): a novel approach to breast surgery. *Rev Esp Anestesiol Reanim.* 2012;59:470–475.

Bashandy GM, Abbas DN. Pectoral nerves I and II blocks in multimodal analgesia for breast cancer surgery: a randomized clinical trial. *Reg Anesth Pain Med.* 2015;40:68–74.

El Hawary H, Joshi GP, Janis JE. Practical review of abdominal and breast regional analgesia for plastic surgeons: evidence and techniques. *Plast Reconstr Surg Glob Open.* 2020;8:e3224.

El Hawary H, Abdelhamid K, Meng F, et al. Erector spinae plane block decreases pain and opioid consumption in breast surgery: systematic review. *Plast Reconstr Surg Glob Open.* 2019;7:e2525.

Momoh AO, Hilliard PE, Chung KC. Regional and neuraxial analgesia for plastic surgery: surgeon’s and anesthesiologist’s perspectives. *Plast Reconstr Surg.* 2014;134(4 Suppl 2):588–688.

Rozen WM, Tran TM, Ashton MW, et al. Refining the course of the thoracolumbar nerves: a new understanding of the innervation of the anterior abdominal wall. *Clin Anat.* 2008;21:325–333.

Gurnaney HG, Maxwell LG, Kraemer FW, et al. Prospective randomized observer-blinded study comparing the analgesic efficacy of ultrasound-guided rectus sheath block and local anaesthetic infiltration for umbilical hernia repair. *Br J Anaesth.* 2011;107:790–795.

Azemati S, Khosravi MB. An assessment of the value of rectus sheath block for postlaparoscopic pain in gynecologic surgery. *J Minim Invasive Gynecol.* 2005;12:12–15.

Khansa I, Koogler A, Richards J, et al. Pain management in abdominal wall reconstruction. *Plast Reconstr Surg Glob Open.* 2017;5:e1400.

Barker JC, DiBartola K, Wee C, et al. Preoperative multimodal analgesia decreases postanesthesia care unit narcotic use and pain scores in outpatient breast surgery. *Plast Reconstr Surg.* 2018;142:443e–450e.

Khansa I, Jefferson R, Khansa L, et al. Optimal pain control in abdominal wall reconstruction. *Plast Reconstr Surg.* 2018;142:1428–1488.